NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease

Share

NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease (via PR Newswire)

REHOVOT, Israel, March 11, 2014 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary…

Click for a printer friendly version

Back to top